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Abstract: The power of rhodium carbene methodology in chemistry is demonstrated by the synthesis of a 
structurally complex polyazole antibiotic. Plantazolicin A, a novel soil bacterium metabolite, comprises a linear 
array of 10 five-membered rings in two pentacyclic regions that derive from ribosomal peptide synthesis followed 
by extensive post-translational modification. The compound possesses potent antimicrobial activity, and is 
selectively active against the anthrax causing organism. A conceptually different synthesis of plantazolicin A is 
reported in which the key steps are the use of rhodium(II)-catalyzed reactions of diazocarbonyl compounds to 
generate up to six of the seven oxazole rings of the antibiotic. NMR Spectroscopic studies and molecular 
modeling, reveal a likely dynamic hairpin conformation with a hinge region around the two isoleucine residues. 
The compound has modest activity against methicillin-resistant Staphylococcus aureus (MRSA).  
In the one and a half centuries since August Kekulé and Archibald Scott Couper independently proposed that a 
carbon atom could form four bonds to other atoms (including other carbons),[1,2] the existence of divalent carbons 
species with a 6-electron valence shell has intrigued chemists. Once regarded as mechanistic curiosities or 
fleeting intermediates, such divalent species, now known as carbenes, have moved center stage as a result of 
the isolation of the first stable carbene in the late 1980s,[3] to be followed by the now familiar stable N-heterocyclic 
carbenes,[4] that as ligands have revolutionalized transition-metal catalysis.[5] Also metallocarbene intermediates, 
derived from diazo compounds, participate in a plethora of reactions that are useful in chemical synthesis.[6] We 
now demonstrate the power of carbene chemistry in the synthesis of the structurally unique, complex polyazole 
antibiotic plantazolicin A, in which upto six of the seven 5-membered oxazole rings of the natural product 
originate from simple precursors such as carboxamides or nitriles facilitated by carbene methodology (Scheme 
1).[7-10]  
Plantazolicin A 1 and plantazolicin B 2 are novel metabolites isolated from the soil bacterium Bacillus 
amyloliquefaciens FZB42.[11,12] The structures consist of a linear array of 5-membered rings (azoles) that 
biosynthetically derive from amino acids by ribosomal peptide synthesis followed by wide-ranging post-
translational modification.[13-15] However, it is the potent antimicrobial activity of plantazolicin A against Gram 
positive organisms that has attracted much attention. In particular, the compound is selectively active against the 
anthrax causing organism Bacillus anthracis (Sterne).[11,13] Although the polyazole nature of plantazolicin A is 
highly reminiscent of the thiopeptide antibiotics,[16-18] a synthetic derivative of which has entered the clinic against 
Clostridium difficile infections,[19,20] there are key differences. Specifically, the linear nature of the antibiotic with its 
two pentacyclic regions represents a challenge for chemical synthesis that, in combination with the antimicrobial 
activity, makes plantazolicin A highly attractive for further study. In this regard, the first total synthesis was 
reported by Süssmuth et al. in 2013,[21] and very recently, a second total synthesis by Ley and co-workers,[22] 
both syntheses  relying on classical peptide coupling. We now report a conceptually different synthesis of 
plantazolicin A based on carbene chemistry. 
 
Scheme 1. Oxazoles from carboxamides and nitriles via rhodium carbenes. 
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Our strategy was to construct the azole rings using the afore-mentioned carbene chemistry, and hence our 
retrosynthetic analysis divided the molecule into two fragments 3 and 4, each adorned with appropriate protecting 
groups, with the sensitive oxazoline ring in the C-terminus right hand fragment 4 to be formed by a late stage 
cyclodehydration reaction (Scheme 2). In contrast with other approaches, we elected to introduce the guanidine 
moiety later in the synthesis. Thus the starting point for our synthesis was the known ornithine-derived thiazole-4-
ester 5,[23] readily converted into the corresponding carboxamide 6 setting the scene for our first carbene step 
(Scheme 3). The key metallocarbene N-H insertion was carried out by slow addition of methyl 2-diazo-3-
oxobutanoate to amide 6 in the presence of 2.5 mol% of rhodium(II) acetate dimer in chloroform, to give the 
ketoamide 7, which was immediately cyclized to oxazole 8 by cyclodehydration with triphenylphosphine and 
iodine in the presence of base.[24] However, it proved difficult to isolate the product from triphenylphosphine oxide, 
ameliorated by use of polymer-supported triphenylphosphine. The ester 8 was converted into the corresponding 
carboxamide 9 and hence the thiocarboxamide 10 by treatment with Lawesson’s reagent. A Hantzsch reaction 
formed the next ring and delivered the three-azole array 11 (Scheme 3), and with two further oxazoles to install, 
an iterative carbene carboxamide N-H insertion cyclodehydration sequence was instigated. Thus ester 11 was 
converted into carboxamide 12 that underwent the desired carbene insertion to give ketoamide 13, 
cyclodehydration of which gave tetra-azole 14 in 52% yield over two steps. A second iteration by way of 
carboxamide 15 and ketoamide 16 produced the desired penta-azole 17, although the yield of this last ring-
forming step was poor. 
 
 
Scheme 2. Retrosynthetic analysis of plantazolicin A. 
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Scheme 3. Synthesis of intermediate penta-azole 17. Reagents and Conditions. a) 35% aq NH3 solution, EtOH, 
rt, 93%; b) methyl 2-diazo-3-oxobutanoate (1.4 equiv), rhodium(II) acetate dimer (2.5 mol%), CHCl3, 60 °C; c) 
Polymer-Ph3P (1.6 equiv), I2 (1.6 equiv), Et3N (3.2 equiv), CH2Cl2, rt, 72% (2 steps); d) ammonia, MeOH, THF, rt, 
80%; e) Lawesson’s reagent (0.7 equiv), CHCl3, rt, 55%; f) ethyl bromopyruvate (5.0 equiv), KHCO3 (10 equiv), 
DME, -10 °C; g) trifluoroacetic anhydride (5 equiv), 2,6-lutidine (10 equiv), DME, -10 °C; h) K2CO3 (5.0 equiv), 
EtOH, H2O, rt, 71% (3 steps); i) 35% aq NH3 solution, EtOH, rt, 84%; j) methyl 2-diazo-3-oxobutanoate (1.4 
equiv), rhodium(II) acetate dimer (2.5 mol%), CHCl3, 60 °C; k) Polymer-Ph3P (3.5 equiv), I2 (3.5 equiv), Et3N (7.0 
equiv), CH2Cl2, rt, 52% (2 steps); l) LiOH, MeOH, THF, rt, 93%; m) EtO2CCl, Et3N, THF, 35% aq NH3 solution, rt, 
57%; n) methyl 2-diazo-3-oxobutanoate (1.4 equiv), rhodium(II) acetate dimer (2.5 mol%), CHCl3, 60 °C; o) 
Polymer-Ph3P (4.0 equiv), I2 (4.0 equiv), Et3N (8.0 equiv), CH2Cl2, rt, 11% (2 steps). [DME = 1,2-
dimethoxyethane] 
In view of the unsatisfactory formation of the fifth and final ring in the penta-azole 17, we sought an alternative, 
whilst still satisfying our desire to use carbene methodology to construct the azole rings. Thus the protected 
threoninamide 18 underwent rhodium(II) catalyzed N-H insertion followed by cyclodehydration to give oxazole 
ester 20 in good yield, deprotection of which resulted in the free threonine-oxazole 21 (Scheme 4). This amine 
was then coupled with the thiazolecarboxylate derived by simple hydrolysis of the bis-thiazolyloxazole 11 
resulting in the formation of the linear tetra-azole 22. Subsequent ring closure of the threonine fragment using 
DAST methodology gave oxazoline 23,[25] dehydrogenative aromatization of which with the 
bromotrichloromethane protocol[26] returned the previously prepared penta-azole 17. With an improved route 
available to the key penta-azole available, the synthesis rapidly progressed towards the complete left-hand 
fragment 3 of the antibiotic. Acid mediated removal of the Boc-group allowed for installation of the dimethylamino 
group by a reductive amination reaction with formaldehyde to give 25, which underwent cleavage of the  
iterated to deliver the bis-oxazole ester 35 by conversion of oxazole ester 32 into nitrile 34 and thereafter a 
second rhodium carbene step. Meanwhile, nitrile 37 also underwent rhodium carbene cycloaddition to give 
oxazole 38,[10] which was deprotected to amine 39 in preparation for union with the bis-oxazole fragment. Bis-
oxazole ester 35 was hydrolyzed to acid 36, subsequently coupled to amine 39 under the HBTU protocol  
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Scheme 4. Synthesis of left-hand penta-azole fragment 3. Reagents and Conditions. a) methyl 2-diazo-3-
oxobutanoate (1.4 equiv), rhodium(II) acetate dimer (2.5 mol%), CHCl3, 70 °C, 16 h, quant.; b) Ph3P (2.0 equiv), 
I2 (2.0 equiv), Et3N (4.0 equiv), CH2Cl2, rt, 55%; c) 4 M HCl in 1,4-dioxane, rt, 6 h, quant.; d) LiOH, MeOH-THF-
H2O (1:5:5), rt, 15 h, 82%; e) HBTU, Et3N, CH2Cl2, rt, 92%; f) DAST, K2CO3, CH2Cl2, -78 °C; g) BrCCl3, DBU, 
CH2Cl2, 0 °C – rt, 32%; h) 4 M HCl in dioxane, rt, quant.; i) NaOAc•3H2O (56 equiv), formaldehyde (37% solution 
in H2O, 30 equiv), NaBH3CN (23 equiv), THF, rt, 63%; j) HBr (33% solution in AcOH; 100 equiv), rt, quant.; k) 27 
(1.4 equiv), Et3N (2.8 equiv), CHCl3, 40%; l) Me3SnOH (10 equiv), DCE, 80 °C, quant. [HBTU = (2-(1H-
benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate; DAST = dimethylamino sulfur trifluoride; DBU 
= 1,8-diazabicyclo[5.4.0]undec-7-ene; DCE = 1,2-dichloroethane] 
remaining N-protecting group in preparation for the introduction of the 2-trimethylsilylethoxycarbonyl (Teoc) 
protected guanidine onto amine 26. To this end, we developed a new reagent, the pyrazole carboxamidine 27, 
that successfully incorporated the protected guanidine to give penta-azole 28, which underwent final ester 
removal to give the desired fragment 3 (Scheme 4) in 1.2% overall yield over 17 steps. 
The presence of four C-5 unsubstituted oxazoles in the C-terminus fragment of the antibiotic, in contrast to the 
three 5-methyloxazoles present in the N-terminal fragment 3, necessitated a slight change in methodology. Thus, 
the order of steps was reversed with the carboxamide being initially dehydrated to the nitrile, with subsequent 
direct conversion into the oxazole in the rhodium catalyzed carbene step (Scheme 1).[10,27] Hence the synthesis of 
fragment 4 started with the known isoleucine-isoleucine dipeptide 29,[28] that was converted into the carboxamide 
30 and hence the required nitrile 31 (Scheme 5). This set the stage for the direct installation of the first oxazole 
32 by dirhodium(II)-catalyzed reaction with the formyl diazo compound, ethyl 2-diazo-3-oxopropanoate, although 
a change in catalyst to dirhodium tetrakis-(heptafluorobutyramide) was beneficial.[27] The sequence was  
to give adduct 40. A DAST-mediated cyclodehydration and aromatization completed the linear array 41 of four 
oxazoles, subsequently hydrolyzed to the corresponding carboxylic acid 42 for further elaboration (Scheme 5). 
Separately, Boc-Phe-OH was protected as its 2-trimethylsilylethyl (TMSE) ester 43, the Boc group cleaved and 
the ensuing amine 44 united with N-Boc-allothreonine to give dipeptide 45. The dipeptide was deprotected in acid 
and the resulting amine 46 underwent coupling with the tetra-oxazole acid 42 to give, after removal of the Boc 
group, the complete C-terminal fragment 4 in 1.7% overall yield over 13 steps from the isoleucine dipeptide 29. 
With both the N- and C-terminal halves of the antibiotic successfully obtained, polyazoles 3 and 4 were united 
in the presence of HBTU and Et3N to give the coupled product 48. The threonine moiety of the intermediate 48 
was cyclized in the presence of DAST to afford the oxazoline 49, the 1H-NMR and 13C-NMR spectroscopic data 
of which matched an intermediate prepared in an earlier synthesis.[21] All that remained was to remove the three 
silicon-based protecting group, and in common with previous workers, we found that this was not completely 
straightforward, and required a two-stage strategy involving sequential use of two fluoride based reagents to 
complete the 
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Scheme 5. Synthesis of right-hand tetra-azole fragment 4. Reagents and Conditions. a) ammonia, MeOH, THF, 
rt, 76%; b) DBU (5.0 equiv), ethyl dichlorophosphate (3.0 equiv), CH2Cl2, 0 °C, 80%; c) ethyl 2-diazo-3-
oxopropanoate (3.0 equiv), rhodium(II) perfluorobutyramide dimer (2.5 mol%), CHCl3, 60 °C, 53%; d) ammonia, 
EtOH, THF, rt, 89%; e) DBU (5.0 equiv), ethyl dichlorophosphate (3.0 equiv), CH2Cl2, 0 °C, 79%; f) ethyl 2-diazo-
3-oxopropanoate (3.0 equiv), rhodium(II) perfluorobutyramide dimer (2.5 mol%), CHCl3, 60 °C, 59%; g) LiOH (58 
equiv), H2O, EtOH, THF, rt, 65%; h) ethyl 2-diazo-3-oxopropanoate (3.0 equiv), rhodium(II) perfluorobutyramide 
dimer (2.5 mol%), CHCl3, 60 °C, 51%; i) 2 M HCl in ether, rt, quant; j) HBTU (1.5 equiv), 39 (1.5 equiv), Et3N (2.0 
equiv), CH2Cl2-DMF, rt, 76%; k) DAST (1.7 equiv), K2CO3 (5.0 equiv), CH2Cl2, -78 °C, quant; l) BrCCl3 (4.0 equiv), 
DBU ( 4.0 equiv), CH2Cl2, 0 °C, 59% (2 steps); m) LiOH (29 equiv), H2O, EtOH, THF, rt, 76%; n) 4 M HCl in 
dioxane, rt, 56%; o) Boc allothreonine (1.0 equiv), HBTU (2.0 equiv), 44 (2.0 equiv), Et3N (4.0 equiv), CH2Cl2-
DMF, rt, 65%; p) 4 M HCl in dioxane, rt, 79%; q) HBTU (1.5 equiv), 46 (1.5 equiv), Et3N (3.0 equiv), CH2Cl2-DMF, 
rt, 58%; r) 4 M HCl in dioxane, rt, quant; s) HBTU (1.3 equiv), 3, Et3N (2.4 equiv), CH2Cl2, rt, 50%; t) DAST (30.0 
equiv.), CH2Cl2, -10 °C, 52%; u) TASF (30.0 equiv.), DMSO, rt; v) HFIP, rt, 31%. [TMSE = 2-trimethylsilylethyl; 
TASF = tris(dimethylamino)sulfonium difluorotrimethylsilicate; HFIP = hexafluoroisopropanol]  
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total synthesis (Scheme 5). Following purification by HPLC, the NMR spectroscopic data of our synthetic material 
matched those reported for the natural antibiotic (Tables S1 and S2); the compound also co-eluted on HPLC with 
authentic material (Figures S1-S3). Our synthetic material also exhibited modest potency against methicillin-
resistant Staphylococcus aureus (MRSA) with an MIC >33 µg/mL (cf. >128 µg/mL[13]). 
Finally, we were interested in the conformation of plantazolicin A. NMR spectroscopy NOESY and TOCSY 
experiments were carried out (see SI) along with molecular modeling. The lack of long range NOEs suggests a 
moderately dynamic molecule with rigid oxazole/thiazole arms that are not in close contact for any appreciable 
time. However, the strong NOEs around the central two isoleucine residues suggest this could act as a hinge 
region leading to a dynamic hair pin conformation. A structure consistent with these data is shown in Figure 1.  
The carbene-based synthesis described above is not only a practical route to provide further quantities of 
the fascinating antimicrobial agent plantazolicin A, it also makes available a wide range fragment structures and 
analogues that are not available by Nature’s biosynthetic machinery. The full biological evaluation of these novel 
structures is underway. 
 
Figure 1. Most probable conformation of plantazolicin A based on NMR spectroscopy and molecular modeling. 
Experimental Section 
All experimental procedures, characterization data for all compounds and copies of the 1H and 13C NMR spectra 
are given in the Supporting Information associated with this paper. 
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